About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNPhase 3NCT01766323

Palliative Morphine With or Without Concurrent Modafinil

Oral morphine is often utilized as a convenient and effective method of achieving palliation of pain in the terminally ill cancer patients. However, at effective doses, a majority of patients do exper...

Lead sponsor: Dr. Rajendra Prasad Government Medical College•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Swaroop Revannasiddaiah, MD

CONTACT

918971862565 swarooptheone@gmail.com

Muninder K Negi, MD

CONTACT

919805192039 lippa@rediffmail.com

Sponsors

Lead Sponsor

Dr. Rajendra Prasad Government Medical College

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Diagnosed and confirmed malignancy
•Able to orally consume tablets
•Blood Pressure: Systolic \<144mmHg; Diastolic \<92mmHg
•Normal blood sugar
•No active systemic infections
•Consenting
•Oral morphine being consumed as a part of terminal symptom palliation

Exclusion Criteria

•Candidates receiving oral morphine for temporary pain management, such as being potential candidates for radical curative approaches in the future
•Poor performance status (Karnofsky Performance Status score \<50)
•Prior history of hypertension, diabetes, tuberculosis, epilepsy
•Prior history of psychiatric and neurological illness

Related studies

RECRUITINGPhase 3

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137 · Non Small Cell Lung Cancer

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

NCT07586215 · Breast Cancer Metastatic

RECRUITINGPhase 3

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357 · Biliary Tract Cancer

RECRUITINGPhase 3

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

RECRUITINGPhase 2

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

NCT06980038 · Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 11, 2013Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE3

Enrollment200

Start dateSep 2012

Last updatedJan 11, 2013

Condition

Cancer Pain Palliation Excessive Sleepiness

Locations shown

Tanda Government Medical College and Hospital

Kangra, Himachal Pradesh

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 11, 2013Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions